Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Cadila Healthcare Sued by Alpex Pharma Over Generic Drug

June 27 (Bloomberg) -- Cadila Healthcare Ltd. a generic-drug maker based in Ahmedabad, India, was sued by Alpex Pharma SA for infringing a U.S. patent for the obesity drug Suprenza.

Alpex, based in Mezzovico, Switzerland, contends Cadila, doing business as Zydus Cadila, wrongly applied to the U.S. Food & Drug Administration to sell low-cost copies of the medicine before the patent expires in 2018, according to a lawsuit filed yesterday in federal court in Wilmington, Delaware.

Unless blocked by a judge, premature sales of the generic drug in the U.S. will cause “substantial and irreparable harm” to Alpex, the company said in court papers.

Sujatha Rajesh, a Cadila spokeswoman, didn’t immediately respond to an e-mailed request for comment on the lawsuit.

The case is Alpex v. Zydus, 13-cv-01143, U.S. District Court, District of Delaware (Wilmington).

To see the patent, click: 6,149,938.

To contact the reporter on this story: Phil Milford in Wilmington at pmilford@bloomberg.net.

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.